Nasdaq · Healthcare
Adaptive Biotechnologies Corp (ADPT)
As-reported financials and recent SEC filings for Adaptive Biotechnologies Corp, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$277.0M
Net income
$-59.5M
Net margin
-21.5%
Diluted EPS
$-0.39
ROE
-26.4%
P/E (TTM)
—
Market cap
$3.35B
Debt / equity
0.6×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $277.0M | $179.0M | $170.3M | $185.3M | $154.3M |
| Gross profit | $205.6M | $106.9M | $94.7M | $127.4M | $105.0M |
| Operating income | $-57.1M | $-162.5M | $-227.0M | $-200.2M | $-209.0M |
| Net income | $-59.5M | $-159.5M | $-225.3M | $-200.2M | $-207.3M |
| Diluted EPS | $-0.39 | $-1.08 | $-1.56 | $-1.40 | $-1.48 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-06-26
View on EDGAR →1442026-06-25
View on EDGAR →1442026-06-25
View on EDGAR →8-K2026-06-22
View on EDGAR →42026-06-17
View on EDGAR →1442026-06-16
View on EDGAR →1442026-06-15
View on EDGAR →42026-06-15
View on EDGAR →Go deeper on ADPT
Search Adaptive Biotechnologies Corp’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.